RxDoctor Payments Data

Karenton Mordi

Psychiatric/Mental Health · Camden, NJNPI 1831675636

Payments from drug & device makers

$798in general payments, 2019–2025

Across 33 payments — averaging $24.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$259
  • AbbVie$138
  • E.r. Squibb & Sons, L.L.C.$117
  • Otsuka America Pharmaceutical, Inc.$91
  • Teva Pharmaceuticals USA, Inc.$80
  • Almatica Pharma LLC$49
  • plus $64 from 3 others

What the payments were for

  • Food & beverage$798100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$798 in reported general payments places this provider in the 60th percentile of 1,212 psychiatric/mental health providers in New Jersey.

See all psychiatric/mental health providers in New Jersey

Medicare billing

Part B allowed, 2024
$28,601
Medicare patients
50
Services billed
360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl14$22,815
Quetiapine Fumarate61$1,372
Alprazolam54$555
Quetiapine Fumarate ErQuetiapine Fumarate13$515
Methylphenidate ErMethylphenidate Hcl22$405
Gabapentin23$394
Clonazepam49$348
Hydroxyzine Hcl19$320
Trazodone Hcl36$299
Prazosin Hcl12$278
Paroxetine Hcl14$245
Buspirone Hcl18$172
Bupropion XlBupropion Hcl13$169
Escitalopram Oxalate27$151
Sertraline Hcl16$151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$138$22,81514 claims
Almatica Pharma LLCSertraline Hcl$49$15116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,212 psychiatric/mental health providers in New Jersey.

Other psychiatric/mental health in Camden

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →